Health TidingsCamurus CAM2029 NDA Accepted by FDA for Acromegaly Camurus CAM2029 NDA Accepted by FDA for Acromegaly Read Post »
Clinical TrialsTakeda’s Zasocitinib Shows Phase 3 Efficacy in Scalp, Nail, Palmoplantar ... Takeda’s Zasocitinib Shows Phase 3 Efficacy in Scalp, Nail, Palmoplantar ... Read Post »
Clinical TrialsVeradermics Reports Positive Age-Based Phase 2/3 Data for VDPHL01 in Male H... Veradermics Reports Positive Age-Based Phase 2/3 Data for VDPHL01 in Male H... Read Post »
Clinical TrialsEvaxion Reports Three-Year EVX-01 Phase 2 Melanoma Results at ESMO 2026 Evaxion Reports Three-Year EVX-01 Phase 2 Melanoma Results at ESMO 2026 Read Post »
Health TidingsShionogi’s Fetroja sNDA Accepted by FDA for Pediatric Hospital Pneumonia ... Shionogi’s Fetroja sNDA Accepted by FDA for Pediatric Hospital Pneumonia ... Read Post »
Health TidingsFabhalta Secures Full FDA Approval to Slow Kidney Function Decline in IgA N... Fabhalta Secures Full FDA Approval to Slow Kidney Function Decline in IgA N... Read Post »
Clinical TrialsKalaris Reports Positive Phase 1a Results for TH103 in Neovascular AMD Kalaris Reports Positive Phase 1a Results for TH103 in Neovascular AMD Read Post »
Clinical TrialsGSK Ends Camlipixant Development After Mixed CALM Phase III Results GSK Ends Camlipixant Development After Mixed CALM Phase III Results Read Post »
Health TidingsDimerix Acquires Phase 2-Ready DMX-652 for Acute Kidney Injury Dimerix Acquires Phase 2-Ready DMX-652 for Acute Kidney Injury Read Post »
New Drug ApprovalEuropean Commission Approves JASCAYD® (Nerandomilast) for Adults with IPF ... European Commission Approves JASCAYD® (Nerandomilast) for Adults with IPF ... Read Post »
Clinical TrialsFirst KRAS Vaccine Shows Promise for Pancreatic Cancer Prevention First KRAS Vaccine Shows Promise for Pancreatic Cancer Prevention Read Post »
Clinical TrialsModerna Advances mRNA-4200 into Phase 1 Study for Advanced Solid Tumors Moderna Advances mRNA-4200 into Phase 1 Study for Advanced Solid Tumors Read Post »
Health TidingsTrellis Raises $9M to Advance Calpurbatug Phase 2 in Prosthetic Joint Infec... Trellis Raises $9M to Advance Calpurbatug Phase 2 in Prosthetic Joint Infec... Read Post »
Health TidingsMedicus Advances Optimized Phase 2 Teverelix Trial After FDA Feedback Medicus Advances Optimized Phase 2 Teverelix Trial After FDA Feedback Read Post »
Health TidingsKalshi and AppliedXL Launch Prediction Markets for Clinical Trial Outcomes Kalshi and AppliedXL Launch Prediction Markets for Clinical Trial Outcomes Read Post »
Clinical TrialsMeiji Seika Highlights Phase III Nacubactam Trial Results Meiji Seika Highlights Phase III Nacubactam Trial Results Read Post »
ManufacturingGates MRI Taps GSK’s AS01E Adjuvant and Serum Institute of India̵... Gates MRI Taps GSK’s AS01E Adjuvant and Serum Institute of India̵... Read Post »
Clinical TrialsBoehringer Ingelheim Advances First-in-Class Triple Agonist BI 3034701 Into... Boehringer Ingelheim Advances First-in-Class Triple Agonist BI 3034701 Into... Read Post »
New Drug ApprovalNICE Recommends Finerenone for Chronic Heart Failure with Preserved or Mild... NICE Recommends Finerenone for Chronic Heart Failure with Preserved or Mild... Read Post »
Health TidingsCOMP360 Phase 2 Analysis Supports Psilocybin Effects in PTSD COMP360 Phase 2 Analysis Supports Psilocybin Effects in PTSD Read Post »
Clinical TrialsAelis Farma Phase 2b Trial of AEF0217 Clears First IDMC Safety Review in Do... Aelis Farma Phase 2b Trial of AEF0217 Clears First IDMC Safety Review in Do... Read Post »
Health Tidings Mergers & AcquisitionsChai Discovery and argenx Partner to Accelerate AI-Driven De Novo Antibody ... Chai Discovery and argenx Partner to Accelerate AI-Driven De Novo Antibody ... Read Post »
Clinical TrialsKairos Reports Favorable Safety Data for ENV-105 Plus Osimertinib in EGFR-M... Kairos Reports Favorable Safety Data for ENV-105 Plus Osimertinib in EGFR-M... Read Post »
Health Tidings Mergers & AcquisitionsLilly Acquires AtaiBeckley to Advance BPL-003 for Treatment-Resistant Depre... Lilly Acquires AtaiBeckley to Advance BPL-003 for Treatment-Resistant Depre... Read Post »
New Drug ApprovalFDA Approves Merck’s LIPFENDRA as First Oral PCSK9 Inhibitor FDA Approves Merck’s LIPFENDRA as First Oral PCSK9 Inhibitor Read Post »
Clinical TrialsInsmed Report Positive 12-Month Data from the OLE Study of Treprostinil Pal... Insmed Report Positive 12-Month Data from the OLE Study of Treprostinil Pal... Read Post »
Drugs Safety AlertMHRA Warns of Rare Botulism Risk with Botulinum Toxin Products MHRA Warns of Rare Botulism Risk with Botulinum Toxin Products Read Post »
Clinical TrialsChimeric Therapeutics Reports New Tumor Shrinkage Data with CHM CDH17 CAR-T... Chimeric Therapeutics Reports New Tumor Shrinkage Data with CHM CDH17 CAR-T... Read Post »
New Drug ApprovalEuropean Commission Approves Wegovy® Pill as First Oral GLP-1 Therapy for ... European Commission Approves Wegovy® Pill as First Oral GLP-1 Therapy for ... Read Post »
Clinical TrialsORIC Initiates Global Phase 3 Himalayas-1 Trial of Rinzimetostat Plus Darol... ORIC Initiates Global Phase 3 Himalayas-1 Trial of Rinzimetostat Plus Darol... Read Post »
Health TidingsEisai’s Lemborexant Marketing Application Accepted by EMA for Chronic Ins... Eisai’s Lemborexant Marketing Application Accepted by EMA for Chronic Ins... Read Post »
Health TidingsAxsome’s AXS-12 NDA for Narcolepsy Cataplexy Accepted by FDA Axsome’s AXS-12 NDA for Narcolepsy Cataplexy Accepted by FDA Read Post »
Health TidingsVeradermics’ Oral VDPHL01 Shows Strong Hair Growth in Phase 2 Study o... Veradermics’ Oral VDPHL01 Shows Strong Hair Growth in Phase 2 Study o... Read Post »
Health TidingsRAG-17 Reduced SOD1 by 69% in Phase 1 Amyotrophic Lateral Sclerosis Trial RAG-17 Reduced SOD1 by 69% in Phase 1 Amyotrophic Lateral Sclerosis Trial Read Post »
Health TidingsOrelabrutinib Significantly Improves Progression-Free Survival as First-Lin... Orelabrutinib Significantly Improves Progression-Free Survival as First-Lin... Read Post »
Clinical TrialsBPGbio’s BPM31510 Shows Encouraging Survival Signal in Phase 2 Glioblasto... BPGbio’s BPM31510 Shows Encouraging Survival Signal in Phase 2 Glioblasto... Read Post »
Clinical TrialsAllogene’s ALLO-316 Shows 31% Response Rate in CD70-High Advanced Kidney ... Allogene’s ALLO-316 Shows 31% Response Rate in CD70-High Advanced Kidney ... Read Post »
Clinical TrialsBiogen and Eisai Present LEADER Study Results for LEQEMBI at AAIC 2026 Biogen and Eisai Present LEADER Study Results for LEQEMBI at AAIC 2026 Read Post »
Clinical TrialsKelun-Biotech Reports Positive Phase III OptiTROP-Lung06 Results in NSCLC Kelun-Biotech Reports Positive Phase III OptiTROP-Lung06 Results in NSCLC Read Post »
Health TidingsApnimed’s AD109 NDA Accepted by FDA for Obstructive Sleep Apnea Apnimed’s AD109 NDA Accepted by FDA for Obstructive Sleep Apnea Read Post »
Health TidingsFDA Grants Priority Review to Roche’s Gazyva/Gazyvaro for Adults with Pri... FDA Grants Priority Review to Roche’s Gazyva/Gazyvaro for Adults with Pri... Read Post »
Clinical TrialsJAMA Publishes Phase 2 Ceperognastat Trial Results in Early Alzheimer’... JAMA Publishes Phase 2 Ceperognastat Trial Results in Early Alzheimer’... Read Post »
New Drug ApprovalFDA Grants Full Approval to Retevmo for RET Fusion-Positive Solid Tumors Ac... FDA Grants Full Approval to Retevmo for RET Fusion-Positive Solid Tumors Ac... Read Post »
GenericsFDA Approves First Generic Afatinib Tablets for EGFR-Mutated NSCLC FDA Approves First Generic Afatinib Tablets for EGFR-Mutated NSCLC Read Post »
New Drug ApprovalFDA Approves REVTORPYK for PIK3CA Wild-Type HR+/HER2- Advanced Breast Cance... FDA Approves REVTORPYK for PIK3CA Wild-Type HR+/HER2- Advanced Breast Cance... Read Post »
Clinical TrialsMediPharm Reports Positive Phase 2 LiBBY Results for Oral Cannabinoid Thera... MediPharm Reports Positive Phase 2 LiBBY Results for Oral Cannabinoid Thera... Read Post »
Health Tidings Regulatory & Health PolicyFDA Releases First Psychedelic Drug Development Guidance FDA Releases First Psychedelic Drug Development Guidance Read Post »
Clinical TrialsBiogen Advances Diranersen to Phase 3 After Positive CELIA Data Biogen Advances Diranersen to Phase 3 After Positive CELIA Data Read Post »
Clinical TrialsImmutep Reports 30.9-Month Overall Survival in Phase I INSIGHT-003 Trial of... Immutep Reports 30.9-Month Overall Survival in Phase I INSIGHT-003 Trial of... Read Post »
Clinical TrialsHemab Reports Durable Phase 2 Results for Sutacimig in Glanzmann Thrombasth... Hemab Reports Durable Phase 2 Results for Sutacimig in Glanzmann Thrombasth... Read Post »
